Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Analysis of the proteome of intracellular Shigella flexneri reveals pathways important for intracellular growth.

Pieper R, Fisher CR, Suh MJ, Huang ST, Parmar P, Payne SM.

Infect Immun. 2013 Dec;81(12):4635-48. doi: 10.1128/IAI.00975-13. Epub 2013 Oct 7.

2.

Systematic annotation and analysis of "virmugens"-virulence factors whose mutants can be used as live attenuated vaccines.

Racz R, Chung M, Xiang Z, He Y.

Vaccine. 2013 Jan 21;31(5):797-805. doi: 10.1016/j.vaccine.2012.11.066. Epub 2012 Dec 6.

3.

Deletion of internal structured repeats increases the stability of a leucine-rich repeat protein, YopM.

Vieux EF, Barrick D.

Biophys Chem. 2011 Nov;159(1):152-61. doi: 10.1016/j.bpc.2011.06.004. Epub 2011 Jun 22.

4.

Unc119 protects from Shigella infection by inhibiting the Abl family kinases.

Vepachedu R, Karim Z, Patel O, Goplen N, Alam R.

PLoS One. 2009;4(4):e5211. doi: 10.1371/journal.pone.0005211. Epub 2009 Apr 17.

5.

Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB.

Nat Rev Microbiol. 2007 Jul;5(7):540-53. Review.

6.

Enteric pathogens as vaccine vectors for foreign antigen delivery.

Kotton CN, Hohmann EL.

Infect Immun. 2004 Oct;72(10):5535-47. Review. No abstract available.

7.

Phenotypic and genotypic characterization of serologically atypical strains of Shigella flexneri type 4 isolated in Dhaka, Bangladesh.

Talukder KA, Islam MA, Dutta DK, Hassan F, Safa A, Nair GB, Sack DA.

J Clin Microbiol. 2002 Jul;40(7):2490-7.

9.
10.

Parameters underlying successful protection with live attenuated mutants in experimental shigellosis.

Bernardini ML, Arondel J, Martini I, Aidara A, Sansonetti PJ.

Infect Immun. 2001 Feb;69(2):1072-83.

11.

Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine.

Turbyfill KR, Hartman AB, Oaks EV.

Infect Immun. 2000 Dec;68(12):6624-32.

12.
13.
14.

Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.

Kotloff KL, Noriega FR, Samandari T, Sztein MB, Losonsky GA, Nataro JP, Picking WD, Barry EM, Levine MM.

Infect Immun. 2000 Mar;68(3):1034-9.

15.

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602.

Coster TS, Hoge CW, VanDeVerg LL, Hartman AB, Oaks EV, Venkatesan MM, Cohen D, Robin G, Fontaine-Thompson A, Sansonetti PJ, Hale TL.

Infect Immun. 1999 Jul;67(7):3437-43.

16.

Strategy for cross-protection among Shigella flexneri serotypes.

Noriega FR, Liao FM, Maneval DR, Ren S, Formal SB, Levine MM.

Infect Immun. 1999 Feb;67(2):782-8.

18.

Intracellular multiplication and virulence of Shigella flexneri auxotrophic mutants.

Cersini A, Salvia AM, Bernardini ML.

Infect Immun. 1998 Feb;66(2):549-57.

19.

Immunogenicity of IpaC-hybrid proteins expressed in the Shigella flexneri 2a vaccine candidate SC602.

Bârzu S, Arondel J, Guillot S, Sansonetti PJ, Phalipon A.

Infect Immun. 1998 Jan;66(1):77-82.

20.

Construction and characterization of a live attenuated vaccine candidate against Shigella dysenteriae type 1.

Klee SR, Tzschaschel BD, Fält I, Kärnell A, Lindberg AA, Timmis KN, Guzmán CA.

Infect Immun. 1997 Jun;65(6):2112-8.

Supplemental Content

Support Center